789. Evaluation of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence

BACKGROUND: Recurrent Clostridioides difficile infection (rCDI) within 180 days of the index episode is associated with a 33% increase in mortality and, to-date, few treatment options exist to prevent recurrent infection. Bezlotoxumab (BEZ) is a novel therapeutic option for the prevention of rCDI, y...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Tanner M, Howard, Amanda, Schwarz, Kerry, Allen, Lorna, Huang, Misha, Bajrovic, Valida, miller, matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777040/
http://dx.doi.org/10.1093/ofid/ofaa439.979

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777040/
http://dx.doi.org/10.1093/ofid/ofaa439.979

Ejemplares similares